Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of Cemiplimab in Recurrent/Metastatic SCCHN
NCT03198130Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of cemiplimab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baseline at Week 24. Started Jul 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03198130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198130.